Trial Profile
Phase II Trial, Multicentre, Opened Label Evaluating the Pharmacokinetics and the Safety and Toxicity of the Tenofovir-Emtricitabine Combination in Pregnant Women and Infants in Africa and Asia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Acronyms TEmAA
- 02 Feb 2021 Data from 3 studies (TEmAA, IMPAACT P1026 & IMPAACT P1097) were used pharmacokinetic modeling framework to predict neonatal pharmacokinetics of transplacentally acquired emtricitabine, dolutegravir, and raltegravir, published in the Clinical Pharmacokinetics.
- 02 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2009 Additional trial acronym TEmAA identified as reported by ClinicalTrials.gov.